10.3390/ijms21207490 313 XuW.YangH.LiuY.YangY.WangP.KimS
Newer pharmacologic treatments in adults with type 2 diabetes: A clinical guideline from the American College of Physicians
Nestls launch of Vital Pursuit, a frozen meal brand developed specifically for GLP-1 users, represents internal innovation built around the new consumer profile
Today, I am glad I invested in this program
GLP-1 Agonist Semaglutide Brand names: Ozempic (diabetes) Wegovy (weight loss) 1517% Average body weight reduction (STEP trials) Activates GLP-1 receptors in gut and brain Suppresses appetite, slows gastric emptying Regulates blood sugar and insulin response Weekly subcutaneous injection or daily oral (Rybelsus) Cardiovascular outcome data: SELECT trial (2023) Dual GLP-1 + GIP Agonist Tirzepatide Brand names: Mounjaro (diabetes) Zepbound (weight loss) 2022% Average body weight reduction (SURMOUNT trials) Activates both GLP-1 AND GIP receptors Stronger effect on insulin sensitivity than semaglutide alone Greater fat loss, especially visceral fat Weekly subcutaneous injection only Head-to-head vs semaglutide: SURPASS-6 favors tirzepatide The core difference is the receptor target
In our daily Canadian lives, factors like pollution, UV exposure from the summer sun, and even the natural process of ageing can increase the production of these free radicals